Royce & Associates’s Sangamo Therapeutics SGMO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-69,057
| Closed | -$653K | – | 1033 |
|
|
2020
Q3 | $653K | Buy |
69,057
+3,242
| +5% | +$30.7K | 0.01% | 826 |
|
|
2020
Q2 | $590K | Hold |
65,815
| – | – | 0.01% | 844 |
|
|
2020
Q1 | $419K | Hold |
65,815
| – | – | 0.01% | 850 |
|
|
2019
Q4 | $551K | Hold |
65,815
| – | – | ﹤0.01% | 876 |
|
|
2019
Q3 | $596K | Hold |
65,815
| – | – | 0.01% | 874 |
|
|
2019
Q2 | $709K | Hold |
65,815
| – | – | 0.01% | 867 |
|
|
2019
Q1 | $628K | Sell |
65,815
-21,000
| -24% | -$200K | 0.01% | 902 |
|
|
2018
Q4 | $997K | Sell |
86,815
-54,000
| -38% | -$620K | 0.01% | 863 |
|
|
2018
Q3 | $2.39M | Sell |
140,815
-115,000
| -45% | -$1.95M | 0.02% | 795 |
|
|
2018
Q2 | $3.63M | Buy |
255,815
+71,150
| +39% | +$1.01M | 0.03% | 683 |
|
|
2018
Q1 | $3.51M | Sell |
184,665
-146,300
| -44% | -$2.78M | 0.02% | 676 |
|
|
2017
Q4 | $5.43M | Sell |
330,965
-147,500
| -31% | -$2.42M | 0.04% | 563 |
|
|
2017
Q3 | $7.18M | Sell |
478,465
-272,635
| -36% | -$4.09M | 0.05% | 469 |
|
|
2017
Q2 | $6.61M | Hold |
751,100
| – | – | 0.04% | 501 |
|
|
2017
Q1 | $3.91M | Hold |
751,100
| – | – | 0.03% | 664 |
|
|
2016
Q4 | $2.29M | Buy |
751,100
+215,000
| +40% | +$656K | 0.01% | 786 |
|
|
2016
Q3 | $2.48M | Buy |
536,100
+80,000
| +18% | +$370K | 0.02% | 747 |
|
|
2016
Q2 | $2.64M | Hold |
456,100
| – | – | 0.02% | 754 |
|
|
2016
Q1 | $2.76M | Buy |
456,100
+144,000
| +46% | +$871K | 0.02% | 761 |
|
|
2015
Q4 | $2.85M | Buy |
312,100
+100,000
| +47% | +$913K | 0.02% | 781 |
|
|
2015
Q3 | $1.2M | Buy |
+212,100
| New | +$1.2M | 0.01% | 946 |
|